Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.

Although the median RFS did not reach statistical significance between the two cohorts (99.0 days for the non-venetoclax group and 297.0 days for the venetoclax group), it still suggested that a potential clinical benefit of venetoclax-based therapy, warranting further investigation.

also in 111,027 other papers